Press Releases

pSivida MD to ring NASDAQ Closing Bell Boston, MA and Perth, Australia (June 30, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today announced that Dr. Paul Ashton, Managing Director, will ring the NASDAQ Stock Market Closing Bell on Tuesday, July 1, at 4

pSivida Interim results from the 3-month Human PK Medidur FA Study Boston, MA and Perth, Australia (June 27, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today reported the interim three-month safety and efficacy results from the first human

Open Briefing Interview with Managing Director, Dr Paul Ashton - pSivida reincorporation in the US Date of lodgement: 20-Jun-2008 Title: Open Briefing®. pSivida. Reincorporation of pSivida to US Record of interview: corporatefile.com.au pSivida Ltd. (NASDAQ:PSDVV, ASX:PVA, FSE:PSI) has implemented

pSivida Scheme of Arrangement Implemented Boston, MA and Perth, Australia (19 June 2008) - pSivida Corp. (ASX: PVA, NASDAQ: PSDVV, FSE: PSI) announces that the Scheme of Arrangement between pSivida Limited and its shareholders has today been implemented.

NASDAQ Trading To Commence Boston, MA and Perth, Australia (June 11, 2008) – Following approval by the Federal Court of Australia of the reincorporation of pSivida Limited, a Western Australian corporation, to pSivida Corp., a new Delaware, United States corporation, pSivida Corp.

Compliance with ASX Listing Rule 3.1 Boston, MA and Perth, Australia (11 June 2008) - pSivida Limited. (ASX: PSD, NASDAQ: PSDV, FSE: PSI) confirms that it is in compliance with its obligations under ASX Listing Rule 3.1 as at the date of this announcement.

pSivida to present at the Rodman & Renshaw Healthcare Conference in Monte Carlo Boston, MA and Perth, Australia – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Managing Director, Dr Paul Ashton is making a company presentation today at the Rodman & Renshaw 5th

pSivida new trial to treat AMD (age related macular degeneration) Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that enrolment has begun for a clinical trial to assess the safety and efficacy of Medidur™ FA in conjunction with Lucentis®

Shareholder Meeting - 6 June 2008 Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that the Federal Court of Australia had ordered the convening of a meeting of shareholders to be held on 6 June 2008 to vote on the proposed Scheme of Arrangement

Commentary and Highlights

- Reincorporation Plan Announced
- Medidur Collaboration Agreement Amended
- BrachySil Pancreatic Cancer Phase IIa Results
- Pfizer R&D Quarterly Payments Commence

pSivida proposed reincorporation in the US Boston, MA and Perth, Australia (April 18, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, FSE:PSI) today announced that it proposes to reincorporate in the United States. The reincorporation, which is subject to Australian Federal Court and shareholder